| Original language | English (US) |
|---|---|
| Pages (from-to) | E242-E245 |
| Journal | Haematologica |
| Volume | 105 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2020 |
ASJC Scopus subject areas
- Hematology
MD Anderson CCSG core facilities
- Biostatistics Resource Group
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Haematologica, Vol. 105, No. 5, 05.2020, p. E242-E245.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma
AU - Manasanch, Elisabet E.
AU - Shah, Jatin J.
AU - Lee, Hans C.
AU - Weber, Donna M.
AU - Thomas, Sheeba K.
AU - Amini, Behrang
AU - Olsem, Jasper
AU - Crumpton, Brandon
AU - Morphey, Ashley
AU - Berkova, Zuzana
AU - Feng, Lei
AU - Orlowski, Robert Z.
N1 - Funding Information: 1Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX; 2Karyopharm Therapeutics, Newton, MA; 3Department of Diagnostic Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX; 4Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX and 5Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Funding: this work was supported in part by The MD Anderson Cancer Center Support Grant (P30 CA016672), the Leukemia and Lymphoma Society Specialized Center of Research (LLS SCOR), the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the Multiple Myeloma Research Foundation and the University of Texas MD Anderson Moon Shot Program. Funding Information: Acknowledgments: RZO, the Florence Maude Thomas Cancer Research Professor, would like to acknowledge support from the National Cancer Institute (R01s CA184464 and 194264, and U10 CA032102), the Leukemia & Lymphoma Society (SCOR-12206-17), the Adelson Medical Research Foundation, the Brock Family Myeloma Research Fund, and the Jean Clarke High-Risk Myeloma Research Fund. We would like to thank participating patients and their families.
PY - 2020/5
Y1 - 2020/5
UR - http://www.scopus.com/inward/record.url?scp=85085989878&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085989878&partnerID=8YFLogxK
U2 - 10.3324/HAEMATOL.2019.225375
DO - 10.3324/HAEMATOL.2019.225375
M3 - Letter
C2 - 31413094
AN - SCOPUS:85085989878
SN - 0390-6078
VL - 105
SP - E242-E245
JO - Haematologica
JF - Haematologica
IS - 5
ER -